However, the biggest catalyst on the horizon is the pending ODD decision by the U.S. FDA, expected in October or November 2013. A positive decision on this front has the potential to double the shares, and lead to a partnership for KRN5500 from a larger pharmaceutical company that could bring in significant upfront cash. With this cash, Dara can funnel money back to increasing the market and promotion around Soltamox and Gelclair.
News 
Market Data 
Discover 
